Immune responses to zoster vaccines

ABSTRACT There are two licensed herpes zoster vaccines. One is a live vaccine (ZVL) based on an attenuated varicella-zoster virus (VZV). The other is a recombinant vaccine (RZV) based on the VZV glycoprotein E (gE) combined with AS01B, a multicomponent adjuvant system. RZV is superior to ZVL in efficacy, and differs from ZVL in that protection is not diminished by the age of the vaccinee and has not waned significantly during 4 years of follow-up. Immunologic studies demonstrated higher peak memory and persistence of T cell responses in RZV compared with ZVL recipients. RZV recipients also showed development and persistence of polyfunctional T cell responses. Taken together, we conclude that the immunologic data parallel and support the higher efficacy over time of RZV compared with ZVL.

• Publication year

  2019

• Venue

  Human Vaccines & Immunotherapeutics

• Publication date

  2019-01-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/21645515.2018.1560918PMID 30676834PMCID PMC6605864
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A spliced latency-associated VZV transcript maps antisense to the viral transactivator gene 61

  2018cited by this paper
• Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine

  2018cited by this paper
• Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults

  2018cited by this paper
• Th1 memory differentiates recombinant from live herpes zoster vaccines

  2018cited by this paper
• Herpes Zoster Vaccines

  2018cited by this paper
• Efficacy and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients 18 Years of Age or Older: First Results of the Phase 3 Randomized, Placebo-Controlled ZOE-HSCT Clinical Trial

  2018cited by this paper
• Immunogenicity and Safety of a Candidate Subunit Adjuvanted Herpes Zoster Vaccine in Adults with Solid Tumors Vaccinated Before or During Immunosuppressive Chemotherapy Treatment: A Phase II/III, Randomized Clinical Trial

  2017cited by this paper
• Metabolic Phenotypes of Response to Vaccination in Humans.

  2017influential reference
• Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study

  2017cited by this paper
• Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

  2017cited by this paper
• Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity

  2017cited by this paper
• A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of Inactivated Vzv Vaccine (ZVIN) in Recipients of Autologous Hematopoietic Cell Transplants (Auto-Hcts)

  2017cited by this paper
• Immune Senescence Factors Associated with the Immunogenicity of a Live Attenuated Zoster Vaccine (ZV) in Older Adults

  2017influential reference
• Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults with Hematologic Malignancies: A Phase III, Randomized Clinical Trial

  2017cited by this paper
• Immunogenicity and Safety of a Candidate Subunit Adjuvanted Herpes Zoster Vaccine (HZ/su) in Adults Post Renal Transplant: a Phase III Randomized Clinical Trial

  2017cited by this paper
• Varicella-Zoster Virus–Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults

  2017cited by this paper
• Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years.

  2016cited by this paper
• Immunogenicity of Varicella Vaccine and Immunologic Predictors of Response in a Cohort of Elderly Nursing Home Residents.

  2016influential reference
• Diversification of the antigen-specific T cell receptor repertoire after varicella zoster vaccination

  2016cited by this paper
• Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial.

  2016cited by this paper
• Defective T Memory Cell Differentiation after Varicella Zoster Vaccination in Older Individuals

  2016cited by this paper
• Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.

  2016cited by this paper
• The Lymphatic Immune Response Induced by the Adjuvant AS01: A Comparison of Intramuscular and Subcutaneous Immunization Routes

  2016cited by this paper
• Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults.

  2016cited by this paper
• Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

  2016cited by this paper
• Perspectives from man’s best friend: National Academy of Medicine’s Workshop on Comparative Oncology

  2016cited by this paper
• Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial.

  2016cited by this paper
• The herpes zoster subunit vaccine

  2016cited by this paper
• Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.

  2015cited by this paper
• Effector and Central Memory Poly-Functional CD4+ and CD8+ T Cells are Boosted upon ZOSTAVAX® Vaccination

  2015cited by this paper
• Zoster Vaccination Increases the Breadth of CD4+ T Cells Responsive to Varicella Zoster Virus.

  2015cited by this paper
• Long-term persistence of zoster vaccine efficacy.

  2015influential reference
• Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells

  2014cited by this paper
• Systematic review of incidence and complications of herpes zoster: towards a global perspective

  2014influential reference
• Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study.

  2014cited by this paper
• Pathogenesis and Current Approaches to Control of Varicella-Zoster Virus Infections

  2013cited by this paper
• Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults.

  2013cited by this paper
• Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

  2012cited by this paper
• Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice.

  2012cited by this paper
• Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses.

  2010cited by this paper
• VZV T cell-mediated immunity.

  2010cited by this paper
• Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine.

  2009cited by this paper
• Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.

  2008cited by this paper
• A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults

  2007cited by this paper
• A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction.

  2007cited by this paper
• Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study.

  2006cited by this paper
• Stress‐induced subclinical reactivation of varicella zoster virus in astronauts

  2004cited by this paper
• Herpes simplex virus-1 and varicella-zoster virus latency in ganglia

  2003cited by this paper
• Varicella-Zoster Virus DNA in Cells Isolated from Human Trigeminal Ganglia

  2003cited by this paper
• Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants.

  2002cited by this paper
• Subclinical Reactivation of Varicella-Zoster Virus in Immunocompromised and Immunocompetent Individuals

  1998cited by this paper
• Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine.

  1997cited by this paper
• Varicella-zoster virus (VZV) DNA in cerebrospinal fluid of patients infected with human immunodeficiency virus: VZV disease of the central nervous system or subclinical reactivation of VZV infection?

  1997cited by this paper
• Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation.

  1992cited by this paper
• Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients.

  1986cited by this paper
• Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma.

  1980cited by this paper
• The gamma globulins. 3. The antibody deficiency syndromes.

  1966cited by this paper
• The gamma globulins.

  1966cited by this paper
• The gamma globulins. 3. The antibody deficiency syndromes.

  1966cited by this paper
• Disturbances in gamma globulin synthesis as experiments of nature.

  1956cited by this paper

• Recombinant herpes zoster vaccine in patients with autoimmune rheumatic diseases in Brazil: a double-blind, randomised, placebo-controlled, phase 4, non-inferiority study.

  2026cites this paper
• Dose-dependent IFN programs in myeloid cells after mRNA and adenovirus COVID-19 vaccination.

  2026cites this paper
• Impaired cellular immune responses to herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors

  2025influential citation
• Sex and age-related differences in humoral and cellular responses to the recombinant zoster vaccine in people living with HIV.

  2025cites this paper
• The immunogenicity of recombinant zoster vaccination in patients with secondary immunodeficiencies: a literature review

  2025cites this paper
• Herpes Zoster in Hematological Disorders: Pathogenesis, Risk Stratification, and Emerging Strategies for Prevention and Immunization

  2025cites this paper
• Efficacy and safety of a China-developed live attenuated herpes zoster vaccine in Chinese healthy adults aged 40 years and older: a multi-center, randomized, double-blind, placebo-controlled, phase 3 clinical trial.

  2025cites this paper
• Potent and Long‐Lasting Immunogenicity Generated by LNP‐mRNA gE Antigen Against Varicella Zoster Virus via an AI‐Assisted Pipeline

  2025cites this paper
• A novel MF59 and CpG1018 adjuvant combination enhances the humoral and cellular immune responses against a truncated varicella-zoster viral glycoprotein E.

  2025cites this paper
• Antibody Titer Against Varicella Zoster Virus and Recombinant Varicella Zoster Vaccine in Hemodialysis Patients: What We Know, What We Should Know

  2025cites this paper
• Establishment and Preliminary Application of Isoelectric Point (Capillary Electrophoresis) Detection Method for Recombinant Herpes Zoster gE Antigen

  2025cites this paper
• Breakthrough herpes zoster following recombinant zoster vaccinations in a rheumatoid arthritis patient receiving a Janus kinase inhibitor: A case report and literature review.

  2025cites this paper
• Shingrix vaccination for recurrent genital herpes: a real-world clinic experience

  2025cites this paper
• Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques

  2024cites this paper
• Preventing herpes zoster in immunocompromised patients: Current concepts

  2024cites this paper
• Current development of therapeutic vaccines for the treatment of chronic infectious diseases

  2024cites this paper
• A nanoparticle vaccine displaying varicella-zoster virus gE antigen induces a superior cellular immune response than a licensed vaccine in mice and non-human primates

  2024cites this paper
• Le zona – Partie 3 : la prévention du zona et des névralgies post-zostériennes

  2023cites this paper
• Letter to the Editor: Proposal for Th1-Induction Therapy for Atopic Dermatitis: A Possibility for the Use of the Varicella Zoster Virus Vaccine.

  2023cites this paper
• Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster

  2023cites this paper
• Vaccine-Preventable Diseases in Older Adults.

  2023cites this paper
• Top 100 Most-Cited Papers in Herpes Zoster from 2000 to 2022: A Bibliometric Study

  2023cites this paper
• Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors

  2023cites this paper
• Pre-Clinical Development of an Adenovirus Vector Based RSV and Shingles Vaccine Candidate

  2023cites this paper
• An adjuvanted zoster vaccine elicits potent cellular immune responses in mice without QS21

  2022cites this paper
• Immunosenescence and Altered Vaccine Efficiency in Older Subjects: A Myth Difficult to Change

  2022cites this paper
• The Role of Nervous System and Immune System in Herpes Zoster Ophthalmicus Dissemination and Laterality – Current Views

  2022cites this paper
• Immune Responses to Varicella-Zoster Virus Vaccines.

  2022cites this paper
• Fraternal Twins: The Enigmatic Role of the Immune System in Alphaherpesvirus Pathogenesis and Latency and Its Impacts on Vaccine Efficacy

  2022cites this paper
• Ageing of Immune System and Response to a Live-Attenuated Herpes Zoster Vaccine in Lung Transplant Candidates

  2021cites this paper
• Hallmarks of the aging T‐cell system

  2021cites this paper
• Vaccines for older adults

  2021cites this paper
• A Medical Records Review Study Assessing Safety of Zoster Vaccine Recombinant, Adjuvanted in Patients With Rheumatic Disease

  2021cites this paper
• The incidence rate of herpes zoster in inflammatory bowel disease

  2021cites this paper
• Aging and Options to Halt Declining Immunity to Virus Infections

  2021cites this paper
• The frequency of interleukin‐1β‐producing monocytes is significantly associated with varicella‐zoster responses of nursing home residents

  2021cites this paper
• The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine

  2020cites this paper
• Identification and Characterization of CD4+ T Cell Epitopes after Shingrix Vaccination

  2020cites this paper
• What's New in Vaccine Science.

  2020cites this paper
• Vaccination for quality of life: herpes–zoster vaccines

  2019cites this paper
• Updates on immunologic correlates of vaccine-induced protection.

  2019cites this paper